scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
51 hedge funds and large institutions have $127M invested in scPharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 51 → 51 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
1% less capital invested
Capital invested by funds: $129M → $127M (-$1.72M)
2.89% less ownership
Funds ownership: 65.46% → 62.57% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$290K |
| 2 |
Two Sigma Investments
New York
|
+$206K |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$184K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$140K |
| 5 |
Goldman Sachs
New York
|
+$129K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$1.42M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$651K |
| 3 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$605K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$399K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$284K |
SCPH Hedge Fund Activity: Q3 2020 in Review
51 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q3 2020, worth a combined $127M — down 1.3% from $129M a quarter earlier.
Fund positioning in SCPH was balanced in Q3 2020: 6 funds opened new positions, 6 closed out, 17 added to existing stakes and 17 trimmed.
The largest buyer was Northern Trust, adding an estimated $290K. The largest seller was Eversept Partners, cutting an estimated $1.42M.
- 51 institutional investors held scPharmaceuticals (SCPH) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $127M of scPharmaceuticals stock for Q3 2020, down 1.3% quarter-over-quarter.
- 6 funds opened new scPharmaceuticals positions in Q3 2020 and 6 closed out, a net change of 0 holders.
- The largest scPharmaceuticals buyer in Q3 2020 was Northern Trust, an estimated $290K added.
- The largest scPharmaceuticals seller in Q3 2020 was Eversept Partners, an estimated $1.42M sold.
Based on aggregated 13F filings for Q3 2020.